The Galleri test is a blood test that screens for cancer by looking for DNA fragments called cell-free DNA (cfDNA) that are released into the bloodstream by both healthy and cancer cells. The test uses artificial intelligence and genetic sequencing technology to analyze the cfDNA for chemical changes that are specific to cancer cells and not found in healthy cells. The test can screen for signals from more than 50 types of cancer at once, checking over a million DNA sites and more than 100,000 DNA regions.

Invitae is a leading provider of genetic testing services that offers comprehensive solutions to understand your genetic health. They provide various tests, including hereditary cancer testing, cardiovascular disease assessments, genetic testing for rare diseases, and carrier screening for inherited conditions. Invitae’s tests help identify genetic risks, guide treatment decisions, and support personalized healthcare plans, aiming to empower individuals with actionable insights into their genetic makeup.

GeneSight Psychotropic is a pharmacogenomic test which means that it analyzes how your genes may affect medication outcomes. The GeneSight test analyzes clinically important genetic variations in your DNA. Results can inform your healthcare provider about how you may break down or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions. This tailored approach can improve treatment outcomes and reduce trial-and-error in medication selection, enhancing overall mental health care.

Boston Heart Diagnostics is transforming the treatment of cardiovascular disease and related diseases with novel diagnostics, reports, and a personalized, scientifically designed nutrition and lifestyle program that has the power to change the way healthcare providers and patients communicate about heart health. Boston Heart’s Personalized Nutrition and Life Plan leverages lab results and individual food preferences to offer tailored lifestyle recommendations. This helps patients improve their test outcomes and lower their risk of chronic diseases.

Uncovering Rare Obesity focuses on identifying uncommon causes of obesity, particularly those linked to genetic variants in the MC4R pathway, which regulates hunger in the hypothalamus. These genetic variants can lead to early-onset, severe obesity, and hyperphagia, independent of lifestyle factors. The initiative offers genetic testing to pinpoint these rare mutations and provides expert consultations for personalized diagnosis and treatment. It also engages in research to enhance understanding and advocacy for improved treatment options for rare obesity conditions.

Genova Diagnostics is renowned for its advanced functional and integrative medical testing, offering a comprehensive range of services that assess key areas of health, including gastrointestinal function, hormone balance, nutritional status, and immune function. Their innovative tests, such as the GI Effects® Comprehensive Stool Profile and the NutrEval® FMV, provide detailed insights into digestive health, metabolic function, and nutrient deficiencies.